Global X Japan Co. Ltd. Boosts Position in Johnson & Johnson (NYSE:JNJ)

Global X Japan Co. Ltd. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.1% in the 2nd quarter, Holdings Channel.com reports. The firm owned 2,837 shares of the company’s stock after acquiring an additional 236 shares during the quarter. Global X Japan Co. Ltd.’s holdings in Johnson & Johnson were worth $415,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. LGT Fund Management Co Ltd. lifted its stake in Johnson & Johnson by 9.8% during the second quarter. LGT Fund Management Co Ltd. now owns 6,843 shares of the company’s stock worth $1,000,000 after purchasing an additional 613 shares during the last quarter. Lane & Associates LLC lifted its stake in Johnson & Johnson by 2.7% in the second quarter. Lane & Associates LLC now owns 4,251 shares of the company’s stock valued at $621,000 after buying an additional 111 shares during the last quarter. Longfellow Investment Management Co. LLC lifted its stake in Johnson & Johnson by 0.8% in the second quarter. Longfellow Investment Management Co. LLC now owns 13,117 shares of the company’s stock valued at $1,917,000 after buying an additional 106 shares during the last quarter. Liberty Wealth Management LLC lifted its stake in Johnson & Johnson by 680.8% in the second quarter. Liberty Wealth Management LLC now owns 16,396 shares of the company’s stock valued at $2,396,000 after buying an additional 14,296 shares during the last quarter. Finally, Choreo LLC lifted its stake in Johnson & Johnson by 106.1% in the second quarter. Choreo LLC now owns 109,791 shares of the company’s stock valued at $16,075,000 after buying an additional 56,511 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.5 %

Shares of JNJ stock opened at $167.38 on Wednesday. The business’s fifty day moving average price is $158.40 and its 200 day moving average price is $153.85. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market capitalization of $402.92 billion, a PE ratio of 10.44, a P/E/G ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.80 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 2.96%. Johnson & Johnson’s payout ratio is 30.92%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on JNJ. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 30th. TD Securities dropped their target price on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. The Goldman Sachs Group dropped their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Finally, StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, September 6th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.